1 First quarter results ended 31 March First quarter results ended 31 March 2001 2001 Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A
2 Rolf Stahel Rolf Stahel Chief Executive Chief Executive Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A
3 Comment on the “Safe Harbor” Statement under the Comment on the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995 Private Securities Litigation Reform Act of 1995 The statements made during today’s presentation, or in response to The statements made during today’s presentation, or in response to questions during the Question & Answer period, that are not questions during the Question & Answer period, that are not historical facts, are forward- -looking statements that involve risks and looking statements that involve risks and historical facts, are forward uncertainties, including but not limited to, risks associated with the th the uncertainties, including but not limited to, risks associated wi inherent inherent uncertainty uncertainty of of pharmaceutical pharmaceutical research, research, product product development and commercialisation, the impact of competitive development and commercialisation, the impact of competitive products, patents, and other risks and uncertainties, including those those products, patents, and other risks and uncertainties, including detailed from time to time in periodic reports, including the Annual nual detailed from time to time in periodic reports, including the An Report filed on Form 10K by Shire with the Securities and Exchange Report filed on Form 10K by Shire with the Securities and Exchan ge Commission. Commission. A
4 Section 57 Financial Services Act Section 57 Financial Services Act This presentation does not constitute an offer to sell or issue, or a solicitation of any offer to purchase or subscribe for, any ordinary shares in the Company, nor shall it form the basis of, or be relied upon in connection with, any contract for such purchase or subscription. No representation or warranty, express or implied, is made or given by the Company as to the accuracy or completeness of the information or the opinions contained in this presentation and no liability is accepted for any such information or opinions. This document has been issued by, and is the sole responsibility of, Shire Pharmaceuticals Group plc. This document has been approved by Deutsche Bank AG London (“Deutsche Bank”) solely for the purposes of section 57 of the UK Financial Services Act 1986. Deutsche Bank, which is regulated in the United Kingdom by the Securities and Futures Authority Limited, is acting for Shire and no one else in connection with the Merger and will not be responsible to anyone other than Shire for providing the protections afforded to customers of Deutsche Bank nor for providing advice in relation to the Merger. Persons viewing this document are directed to the Shire press announcement dated 11 December 2000, which contains additional details and information relating to the Merger. A
5 Q1 Financial Highlights Q1 Financial Highlights (before APB 25 charge) (before APB 25 charge) � Revenues $155.6m +31% � Revenues $155.6m +31% Operating income $ 42.0m +44% � Operating income $ 42.0m +44% � � Income before tax $ 40.1m +50% � Income before tax $ 40.1m +50% � EPS (diluted) � EPS (diluted) � Ordinary shares 10.7 cents � Ordinary shares 10.7 cents +46% +46% � ADS 32.1 cents � ADS 32.1 cents A
6 Key Product RX Market Share Key Product RX Market Share RX growth Q1 01 March 01 March 00 versus Q1 00* % % % Adderall 33.3 29.7 +20 Agrylin 20.4 14.3 +42 Pentasa 17.8 18.0 +10 ProAmatine 22.1 19.5 +31 Carbatrol 32.5 26.0 +43 A IMS data
7 Development Pipeline Development Pipeline Product Indication Pre-clinical Phase I Phase II Phase III Registration Marketed Central Nervous System Reminyl TM (galantamine) Alzheimer’s disease Dirame TM Analgesia Adderall LA (SLI 381) ADHD SPD 503 ADHD SPD 420 ADHD SPD 417 Bipolar disorder SPD 418 Epilepsy SPD 421 Epilepsy SPD 451 Parkinson’s Disease SPD 502 Stroke Metabolic disease Foznol TM Hyperphosphataemia Oncology / Haematology SPD 424 Prostate cancer SPD 427 Oncology Agrylin TM Thrombocythaemia Gastroenterology Balsalazide Ulcerative colitis Emitasol TM Diabetic gastroparesis Pentasa TM 500mg Ulcerative colitis A
8 Reminyl™ (galantamine) Reminyl™ (galantamine) � UK NICE* announce treatments for Alzheimer’s disease � UK NICE* announce treatments for Alzheimer’s disease should be made available as part of the management of should be made available as part of the management of the disease in the UK the disease in the UK � FDA approval letter received 28 February 2001 � FDA approval letter received 28 February 2001 � Launch planned for May 2001 by Janssen Pharmaceutica � Launch planned for May 2001 by Janssen Pharmaceutica and Ortho McNeil in the US. and Ortho McNeil in the US. * National Institute for Clinical Excellence A
9 Foznol* Foznol* � First European filing submitted on 13 March 2001 � First European filing submitted on 13 March 2001 � US filing expected by late Q4 2001 � US filing expected by late Q4 2001 *Trade Mark under registration A
10 Adderall XR* (SLI 381) Adderall XR* (SLI 381) � Intended Trade Mark Adderall XR* � Intended Trade Mark Adderall XR* � Phase III data to be presented at the annual meeting of � Phase III data to be presented at the annual meeting of the American Psychiatric Association (APA) on 9 May the American Psychiatric Association (APA) on 9 May 2001 at 11:00 am 2001 at 11:00 am *Trade Mark under registration A
11 Agrylin* Agrylin* European Commission granted orphan drug � European Commission granted orphan drug � designation for anagrelide in treatment of designation for anagrelide in treatment of essential thrombocythaemia essential thrombocythaemia � Orphan drug status already granted in US and � Orphan drug status already granted in US and Japan Japan * Trade Mark A
12 Angus Russell Angus Russell Group Finance Director Group Finance Director Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A
13 Key Product Sales Key Product Sales Q1 01 vs Q1 00 Q1 01 vs Q1 00 Q1 01 Q1 00 Sales Scrip* $m $m Growth % Growth % Adderall 70.1 54.5 +29 +20 Agrylin 17.1 11.0 +56 +42 Pentasa 14.4 10.3 +39 +10 ProAmatine 7.6 3.6 +112 +31 Carbatrol 9.6 5.6 +72 +43 *IMS Data A
14 Financial Ratios Financial Ratios (before exceptional charges and APB 25 charge) (before exceptional charges and APB 25 charge) Q1-01 Q1-00 FY00 FY99 % % % % COGS : Product sales 18 18 18 24 Gross margin 82 82 82 76 R&D : Revenues 17 22 21 19 S,G&A (incl D&A) : Revenues 37 36 35 40 S,G&A (excl D&A) : Product sales 33 31 30 34 Operating margin 27 25 28 18 A
15 Cash Flow Cash Flow Q1 2001 Q1 2001 Cash generation +$71m -$14m Tax/interest -$18m Product acquisitions -$2m Fixed Assets Financing +$2m Net cash surplus +$39m A
16 Balance Sheet Balance Sheet 31.3.01 31.3.00 31.12.00 $m $m $m Net Assets 762 631 753 Net Cash 97 (8) 58 Gearing Nil 1% Nil A
17 Rolf Stahel Rolf Stahel Chief Executive Chief Executive Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A
18 Q1 Summary Q1 Summary � Revenue growth 31% � Revenue growth 31% � EPS growth 46% � EPS growth 46% � Reminyl* US approval expected May 2001. Launch by � Reminyl* US approval expected May 2001. Launch by Janssen Pharmaceutica and Ortho McNeil Janssen Pharmaceutica and Ortho McNeil � First European filing of Foznol* � First European filing of Foznol* � Agrylin* receives orphan drug status in Europe � Agrylin* receives orphan drug status in Europe � Extension applied for. Shire remains firmly committed to � Extension applied for. Shire remains firmly committed to gaining Industry Canada’s approval to complete the gaining Industry Canada’s approval to complete the proposed merger with BioChem Pharma Inc proposed merger with BioChem Pharma Inc * Trade mark A
Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A
Recommend
More recommend
